Group 1 - Company Innovent Biologics (1541.HK) announced a placement of 24.2 million new H-shares, representing approximately 5.61% of the enlarged share capital, to raise HKD 351 million (USD 45 million) at a price of HKD 14.5 per share, which is a discount of about 12.97% from the previous closing price of HKD 16.66 [3] - The estimated net proceeds of approximately HKD 345 million will be used to fund the research and development of IMM2510 and IMM27M for the treatment of solid tumors, as well as for the development of IMM01 (Tislelizumab) and IMM0306, and to supplement working capital and general corporate purposes [3] - The company has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510 for the treatment of immune-resistant non-small cell lung cancer (NSCLC) [3] Group 2 - The company's stock opened lower on Thursday, trading at HKD 14.46 at noon, down 13.21%. However, the stock has increased by 180% year-to-date [3]
簡訊：宜明昂科折讓13%配股筹3.5亿港元